Skip to main content

NUEVAS APROXIMACIONES PARA IDENTIFICAR VARIANTES PATOGENICAS EN EXPERIMENTOS DE SECUENCIACION MASIVA BASADAS EN LA INTEGRACION DE IMPACTO MOLECULAR E INFORMACION BIOMEDICA

SAF2016-80255-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

PMut: A web-based tool for the annotation of pathological variants on proteins, 2017 update

  • López Ferrando, Víctor
  • Gazzo, Andrea M.
  • Cruz, Xavier de la
  • Orozco, Modesto
  • Gelpí, Josep Lluís
We present here a full update of the PMut predictor, active since 2005 and with a large acceptance in the field of predicting Mendelian pathological mutations. PMut internal engine has been renewed, and converted into a fully featured standalone training and prediction engine that not only powers PMut web portal, but that can generate custom predictors with alternative training sets or validation schemas. PMut Web portal allows the user to perform pathology predictions, to access a complete repository of pre-calculated predictions, and to generate and validate new predictors. The default predictor performs with good quality scores (MCC values of 0.61 on 10-fold cross validation, and 0.42 on a blind test with SwissVar 2016 mutations). The PMut portal is freely accessible at http://mmb.irbbarcelona.org/PMut. A complete help and tutorial is available at http://mmb.irbbarcelona.org/PMut/help., Spanish Ministry of Science [BIO2015-64802-R-32868, SEV-2015-0493, TIN2012-34557, TEC2015-67774-C2-2-R, SAF2016-80255-R]; Catalan Government [2014-SGR-134, 2014-SGR-1051]; Instituto de Salud Carlos III-Instituto Nacional de Bioinformática [INB; PT13/0001/0019, PT13/0001/0028]; European Union, H2020 programme [Elixir-Excelerate: 676559; BioExcel: 674728 and MuG: 676566]; La Caixa Foundation fellowship [to V.L.F.]. Funding for open access charge: European Union and Spanish Ministry of Science.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence

  • Álvarez de la Campa, Elena
  • Padilla, Natàlia
  • Cruz, Xavier de la
[Background] Strict guidelines delimit the use of computational information in the clinical setting, due to the still moderate accuracy of in silico tools. These guidelines indicate that several tools should always be used and that full coincidence between them is required if we want to consider their results as supporting evidence in medical decision processes. Application of this simple rule certainly decreases the error rate of in silico pathogenicity assignments. However, when predictors disagree this rule results in the rejection of potentially valuable information for a number of variants. In this work, we focus on these variants of the protein sequence and develop specific predictors to help improve the success rate of their annotation., [Results] We have used a set of 59,442 protein sequence variants (15,723 pathological and 43,719 neutral) from 228 proteins to identify those cases for which pathogenicity predictors disagree. We have repeated this process for all the possible combinations of five known methods (SIFT, PolyPhen-2, PON-P2, CADD and MutationTaster2). For each resulting subset we have trained a specific pathogenicity predictor. We find that these specific predictors are able to discriminate between neutral and pathogenic variants, with a success rate different from random. They tend to outperform the constitutive methods but this trend decreases as the performance of the constitutive predictor improves (e.g. with PON-P2 and PolyPhen-2). We also find that specific methods outperform standard consensus methods (Condel and CAROL)., [Conclusion] Focusing development efforts on the case of variants for which known methods disagree we may obtain pathogenicity predictors with improved performances. Although we have not yet reached the success rate that allows the use of this computational evidence in a clinical setting, the simplicity of the approach indicates that more advanced methods may reach this goal in a close future., This work has been supported by the spanish Ministerio de Economía y Competitividad (BIO2012–40133; SAF2016–80255-R). It has also been supported, and the publication costs have been defrayed, by the European Regional Development Fund (ERDF), through the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014–2020), research grant PIREPRED (EFA086/15)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Structural and Computational Characterization of Disease-Related Mutations Involved in Protein-Protein Interfaces

  • Navío, Dàmaris
  • Rosell, Mireia
  • Aguirre, Josu
  • Cruz, Xavier de la
  • Fernández-Recio, Juan
One of the known potential effects of disease-causing amino acid substitutions in proteins is to modulate protein-protein interactions (PPIs). To interpret such variants at the molecular level and to obtain useful information for prediction purposes, it is important to determine whether they are located at protein-protein interfaces, which are composed of two main regions, core and rim, with different evolutionary conservation and physicochemical properties. Here we have performed a structural, energetics and computational analysis of interactions between proteins hosting mutations related to diseases detected in newborn screening. Interface residues were classified as core or rim, showing that the core residues contribute the most to the binding free energy of the PPI. Disease-causing variants are more likely to occur at the interface core region rather than at the interface rim (<i>p</i> < 0.0001). In contrast, neutral variants are more often found at the interface rim or at the non-interacting surface rather than at the interface core region. We also found that arginine, tryptophan, and tyrosine are over-represented among mutated residues leading to disease. These results can enhance our understanding of disease at molecular level and thus contribute towards personalized medicine by helping clinicians to provide adequate diagnosis and treatments., This research was funding by the EU European Regional Development Fund (ERDF) through the Program Interreg V-A Spain-France-Andorra (POCTEFA), by the CSIC (intramural grant number 201720I031), and by the Spanish Ministry of Economy and Competitiveness (grants BIO2016-79930-R and SAF2016-80255-R). M.R. is recipient of an FPI fellowship from the Severo Ochoa program, We acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Ozkan, Selen
Endofenotip; Prediccions de patogenicitat; Predictor específic de proteïna, Endofenotipo; Predicciones de patogenicidad; Predictor específico de proteína, Endophenotype; Pathogenicity predictions; Protein-specific predictor, The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements., This research was funded by the EU European Regional Development Fund (ERDF) through the Program Interreg V-A Spain-France-Andorra (POCTEFA), grant number EFA086/15-PIREPRED, by the Spanish Ministerio de Ciencia e Innovación, grant number PID2019-111217RB-I00, and by the Spanish Ministerio de Economía y Competitividad, grant number SAF2016-80255-R.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Choosing Variant Interpretation Tools for Clinical Applications: Context Matters

  • Aguirre, Josu
  • Padilla Sirera, Natàlia
  • Ozkan, Selen
  • Riera, Casandra
  • Feliubadaló, Lidia
  • De la Cruz Montserrat, Fco. Xavier
Clinical variant interpretation; Healthcare costs; Pathogenicity prediction, Interpretación de variantes clínicas; Costes sanitarios; Predicción de patogenicidad, Interpretació de variants clíniques; Despeses sanitàries; Predicció de patogenicitat, Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers., This work was supported by research grants SAF2016-80255-R from the Spanish Ministerio de Economía y Competitividad (MINECO), PID2019-111217RB-I00 and TED2021-130342B-I00 from the Spanish Ministerio de Ciencia e Innovación, and by the European Regional Development Fund (ERDF) through the Interreg program POCTEFA (Pirepred, EFA086/15).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PMut: A web-based tool for the annotation of pathological variants on proteins, 2017 update

  • López Ferrando, Víctor
  • Gazzo, Andrea M.
  • Cruz, Xavier de la
  • Orozco, Modesto
  • Gelpí, Josep Lluís
We present here a full update of the PMut predictor, active since 2005 and with a large acceptance in the field of predicting Mendelian pathological mutations. PMut internal engine has been renewed, and converted into a fully featured standalone training and prediction engine that not only powers PMut web portal, but that can generate custom predictors with alternative training sets or validation schemas. PMut Web portal allows the user to perform pathology predictions, to access a complete repository of pre-calculated predictions, and to generate and validate new predictors. The default predictor performs with good quality scores (MCC values of 0.61 on 10-fold cross validation, and 0.42 on a blind test with SwissVar 2016 mutations). The PMut portal is freely accessible at http://mmb.irbbarcelona.org/PMut. A complete help and tutorial is available at http://mmb.irbbarcelona.org/PMut/help., Spanish Ministry of Science [BIO2015-64802-R-32868, SEV-2015-0493, TIN2012-34557, TEC2015-67774-C2-2-R, SAF2016-80255-R]; Catalan Government [2014-SGR-134, 2014-SGR-1051]; Instituto de Salud Carlos III-Instituto Nacional de Bioinformática [INB; PT13/0001/0019, PT13/0001/0028]; European Union, H2020 programme [Elixir-Excelerate: 676559; BioExcel: 674728 and MuG: 676566]; La Caixa Foundation fellowship [to V.L.F.]. Funding for open access charge: European Union and Spanish Ministry of Science.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

New genes involved in Angelman syndrome-like: Expanding the genetic spectrum

  • Aguilera, Cinthia
  • Gabau, Elisabeth
  • Ramirez-Mallafre, Ariadna
  • Brun-Gasca, Carme
  • Dominguez-Carral, Jana
  • Delgadillo, Veronica
  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
Síndrome de Angelman; Fenotipo, Síndrome d'Angelman; Fenotip, Angelman syndrome; Phenotype, Angelman syndrome (AS) is a neurogenetic disorder characterized by severe developmental delay with absence of speech, happy disposition, frequent laughter, hyperactivity, stereotypies, ataxia and seizures with specific EEG abnormalities. There is a 10–15% of patients with an AS phenotype whose genetic cause remains unknown (Angelman-like syndrome, AS-like). Whole-exome sequencing (WES) was performed on a cohort of 14 patients with clinical features of AS and no molecular diagnosis. As a result, we identified 10 de novo and 1 X-linked pathogenic/likely pathogenic variants in 10 neurodevelopmental genes (SYNGAP1, VAMP2, TBL1XR1, ASXL3, SATB2, SMARCE1, SPTAN1, KCNQ3, SLC6A1 and LAS1L) and one deleterious de novo variant in a candidate gene (HSF2). Our results highlight the wide genetic heterogeneity in AS-like patients and expands the differential diagnosis., This work is supported by Instituto de Salud Carlos III (MG, PI16/01411), Asociación Española de Síndrome de Angelman (EG), Institut d’investigació i innovació Parc Taulí I3PT (CA, CIR2016/025, CIR2018/021) and Ministerio de Economía y Competitividad (XD, SAF2016-14 80255-R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Álvarez de la Crespo, Elena
Predictors de patogenicitat in silico; Variants missense; Seqüenciació de nova generació, Predictores de patogenicidad in silico; Variantes missense; Secuenciación de nueva generación, In silico pathogenicity predictors; Missense variants; Next-generation sequencing, Background Strict guidelines delimit the use of computational information in the clinical setting, due to the still moderate accuracy of in silico tools. These guidelines indicate that several tools should always be used and that full coincidence between them is required if we want to consider their results as supporting evidence in medical decision processes. Application of this simple rule certainly decreases the error rate of in silico pathogenicity assignments. However, when predictors disagree this rule results in the rejection of potentially valuable information for a number of variants. In this work, we focus on these variants of the protein sequence and develop specific predictors to help improve the success rate of their annotation. Results We have used a set of 59,442 protein sequence variants (15,723 pathological and 43,719 neutral) from 228 proteins to identify those cases for which pathogenicity predictors disagree. We have repeated this process for all the possible combinations of five known methods (SIFT, PolyPhen-2, PON-P2, CADD and MutationTaster2). For each resulting subset we have trained a specific pathogenicity predictor. We find that these specific predictors are able to discriminate between neutral and pathogenic variants, with a success rate different from random. They tend to outperform the constitutive methods but this trend decreases as the performance of the constitutive predictor improves (e.g. with PON-P2 and PolyPhen-2). We also find that specific methods outperform standard consensus methods (Condel and CAROL). Conclusion Focusing development efforts on the case of variants for which known methods disagree we may obtain pathogenicity predictors with improved performances. Although we have not yet reached the success rate that allows the use of this computational evidence in a clinical setting, the simplicity of the approach indicates that more advanced methods may reach this goal in a close future., This work has been supported by the spanish Ministerio de Economía y Competitividad (BIO2012–40133; SAF2016–80255-R). It has also been supported, and the publication costs have been defrayed, by the European Regional Development Fund (ERDF), through the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014–2020), research grant PIREPRED (EFA086/15).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update

  • López-Ferrando, Víctor
  • Gazzo, Andrea
  • de la Cruz, Xavier
  • Orozco, Modesto
  • Gelpí, Josep Lluís
We present here a full update of the PMut predictor, active since 2005 and with a large acceptance in the field of predicting Mendelian pathological mutations. PMut internal engine has been renewed, and converted into a fully featured standalone training and prediction engine that not only powers PMut web portal, but that can generate custom predictors with alternative training sets or validation schemas. PMut Web portal allows the user to perform pathology predictions, to access a complete repository of pre-calculated predictions, and to generate and validate new predictors. The default predictor performs with good quality scores (MCC values of 0.61 on 10-fold cross validation, and 0.42 on a blind test with SwissVar 2016 mutations). The PMut portal is freely accessible at http://mmb.irbbarcelona.org/PMut. A complete help and tutorial is available at http://mmb.irbbarcelona.org/PMut/help., Spanish Ministry of Science [BIO2015-64802-R-32868, SEV-2015-0493, TIN2012-34557, TEC2015-67774-C2-2-R, SAF2016-80255-R]; Catalan Government [2014-SGR-134, 2014-SGR-1051]; Instituto de Salud Carlos III-Instituto Nacional de Bioinformática [INB; PT13/0001/0019, PT13/0001/0028]; European Union, H2020 programme [Elixir-Excelerate: 676559; BioExcel: 674728 and MuG: 676566]; La Caixa Foundation fellowship [to V.L.F.]. Funding for open access charge: European Union and Spanish Ministry of Science., Peer Reviewed, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PMut, a web-based tool for the annotation of pathological variants on proteins, 2017 update

  • López-Ferrando, Víctor
  • Gazzo, Andrea
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Gelpí, Josep Ll|||0000-0002-0566-7723
We present here a full update of the PMut predictor, active since 2005 and with a large acceptance in the field of predicting Mendelian pathological mutations. PMut internal engine has been renewed, and converted into a fully featured standalone training and prediction engine that not only powers PMut web portal, but that can generate custom predictors with alternative training sets or validation schemas. PMut Web portal allows the user to perform pathology predictions, to access a complete repository of pre-calculated predictions, and to generate and validate new predictors. The default predictor performs with good quality scores (MCC values of 0.61 on 10-fold cross validation, and 0.42 on a blind test with SwissVar 2016 mutations). The PMut portal is freely accessible at http://mmb.irbbarcelona.org/PMut. A complete help and tutorial is available at http://mmb.irbbarcelona.org/PMut/help.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity

  • Marín, Òscar
  • Aguirre, Josu|||0000-0002-9601-636X
  • de la Cruz, Xavier|||0000-0002-9738-8472
Compensated pathogenic deviations (CPDs) are sequence variants that are pathogenic in humans but neutral in other species. In recent years, our molecular understanding of CPDs has advanced substantially. For example, it is known that their impact on human proteins is generally milder than that of average pathogenic mutations and that their impact is suppressed in non-human carriers by compensatory mutations. However, prior studies have ignored the evolutionarily relevant relationship between molecular impact and organismal phenotype. Here, we explore this topic using CPDs from FVIII and FIX and data concerning carriers' hemophilia severity. We find that, regardless of their molecular impact, these mutations can be associated with either mild or severe disease phenotypes. Only a weak relationship is found between protein stability changes and severity. We also characterize the population variability of hemostasis proteins, which constitute the genetic background of FVIII and FIX, using data from the 1000 Genome project. We observe that genetic background can vary substantially between individuals in terms of both the amount and nature of genetic variants. Finally, we discuss how these results highlight the need to include new terms in present models of protein evolution to explain the origin of CPDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural and computational characterization of disease-related mutations involved in protein-protein interfaces

  • Navío, D.
  • Rosell, M.
  • Aguirre, Josu|||0000-0002-9601-636X
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Fernández-Recio, Juan|||0000-0002-3986-7686
One of the known potential effects of disease-causing amino acid substitutions in proteins is to modulate protein-protein interactions (PPIs). To interpret such variants at the molecular level and to obtain useful information for prediction purposes, it is important to determine whether they are located at protein-protein interfaces, which are composed of two main regions, core and rim, with different evolutionary conservation and physicochemical properties. Here we have performed a structural, energetics and computational analysis of interactions between proteins hosting mutations related to diseases detected in newborn screening. Interface residues were classified as core or rim, showing that the core residues contribute the most to the binding free energy of the PPI. Disease-causing variants are more likely to occur at the interface core region rather than at the interface rim (p < 0.0001). In contrast, neutral variants are more often found at the interface rim or at the non-interacting surface rather than at the interface core region. We also found that arginine, tryptophan, and tyrosine are over-represented among mutated residues leading to disease. These results can enhance our understanding of disease at molecular level and thus contribute towards personalized medicine by helping clinicians to provide adequate diagnosis and treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence

  • de la Campa, Elena Álvarez
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • de la Cruz, Xavier|||0000-0002-9738-8472
Strict guidelines delimit the use of computational information in the clinical setting, due to the still moderate accuracy of in silico tools. These guidelines indicate that several tools should always be used and that full coincidence between them is required if we want to consider their results as supporting evidence in medical decision processes. Application of this simple rule certainly decreases the error rate of in silico pathogenicity assignments. However, when predictors disagree this rule results in the rejection of potentially valuable information for a number of variants. In this work, we focus on these variants of the protein sequence and develop specific predictors to help improve the success rate of their annotation. We have used a set of 59,442 protein sequence variants (15,723 pathological and 43,719 neutral) from 228 proteins to identify those cases for which pathogenicity predictors disagree. We have repeated this process for all the possible combinations of five known methods (SIFT, PolyPhen-2, PON-P2, CADD and MutationTaster2). For each resulting subset we have trained a specific pathogenicity predictor. We find that these specific predictors are able to discriminate between neutral and pathogenic variants, with a success rate different from random. They tend to outperform the constitutive methods but this trend decreases as the performance of the constitutive predictor improves (e.g. with PON-P2 and PolyPhen-2). We also find that specific methods outperform standard consensus methods (Condel and CAROL). Focusing development efforts on the case of variants for which known methods disagree we may obtain pathogenicity predictors with improved performances. Although we have not yet reached the success rate that allows the use of this computational evidence in a clinical setting, the simplicity of the approach indicates that more advanced methods may reach this goal in a close future. The online version of this article (doi:10.1186/s12864-017-3914-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2, In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • de la Cruz, Xavier|||0000-0002-9738-8472
The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New genes involved in Angelman syndrome-like, Expanding the genetic spectrum

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Ramírez Mallafré, Ariadna|||0000-0002-7897-816X
  • Brun Gasca, Carme|||0000-0002-5651-5842
  • Dominguez-Carral, Jana
  • Delgadillo, Veronica
  • Laurie, Steven|||0000-0003-3913-5829
  • Derdak, Sophia
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Capdevila, Núria|||0000-0003-2080-7381
  • Spataro, Nino|||0000-0002-2127-2238
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Guitart, Maria|||0000-0003-2957-7404
  • Ruiz, Anna|||0000-0001-7314-5962
Angelman syndrome (AS) is a neurogenetic disorder characterized by severe developmental delay with absence of speech, happy disposition, frequent laughter, hyperactivity, stereotypies, ataxia and seizures with specific EEG abnormalities. There is a 10-15% of patients with an AS phenotype whose genetic cause remains unknown (Angelman-like syndrome, AS-like). Whole-exome sequencing (WES) was performed on a cohort of 14 patients with clinical features of AS and no molecular diagnosis. As a result, we identified 10 de novo and 1 X-linked pathogenic/likely pathogenic variants in 10 neurodevelopmental genes (SYNGAP1, VAMP2, TBL1XR1, ASXL3, SATB2, SMARCE1, SPTAN1, KCNQ3, SLC6A1 and LAS1L) and one deleterious de novo variant in a candidate gene (HSF2). Our results highlight the wide genetic heterogeneity in AS-like patients and expands the differential diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods

  • Jain, Shantanu
  • Bakolitsa, Constantina|||0000-0002-6980-9831
  • Brenner, Steven E.
  • Radivojac, Predrag
  • Moult, John
  • Repo, Susanna
  • Hoskins, Roger A.
  • Andreoletti, Gaia
  • Barsky, Daniel
  • Chellapan, Ajithavalli
  • Chu, Hoyin
  • Dabbiru, Navya
  • Kollipara, Naveen K.
  • Ly, Melissa
  • Neumann, Andrew J.
  • Pal, Lipika R.
  • Odell, Eric
  • Pandey, Gaurav
  • Peters-Petrulewicz, Robin C.
  • Srinivasan, Rajgopal
  • Yee, Stephen F.
  • Yeleswarapu, Sri Jyothsna
  • Zuhl, Maya
  • Adebali, Ogun
  • Patra, Ayoti
  • Beer, Michael A.
  • Hosur, Raghavendra
  • Peng, Jian
  • Bernard, Brady M.
  • Berry, Michael
  • Dong, Shengcheng
  • Boyle, Alan P.
  • Adhikari, Aashish
  • Chen, Jingqi
  • Hu, Zhiqiang
  • Wang, Robert
  • Wang, Yaqiong
  • Miller, Maximilian
  • Wang, Yanran
  • Bromberg, Yana
  • Turina, Paola
  • Capriotti, Emidio|||0000-0002-2323-0963
  • Han, James J.
  • Ozturk, Kivilcim
  • Carter, Hannah
  • Babbi, Giulia|||0000-0002-9816-4737
  • Bovo, Samuele
  • Di Lena, Pietro
  • Martelli, Pier Luigi|||0000-0002-0274-5669
  • Savojardo, Castrense
  • Casadio, Rita
  • Cline, Melissa S.
  • De Baets, Greet
  • Bonache, Sandra|||0000-0002-7395-8143
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Fernández, Alejandro
  • Montalban, Gemma|||0000-0002-6958-4759
  • Ootes, Lars
  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • Riera, Casandra
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Diekhans, Mark|||0000-0002-0430-0989
  • Huwe, Peter J.
  • Wei, Qiong
  • Xu, Qifang
  • Dunbrack, Roland L.
  • Gotea, Valer|||0000-0001-7857-3309
  • Elnitski, Laura
  • Margolin, Gennady
  • Fariselli, Piero
  • Kulakovskiy, Ivan V.
  • Makeev, V.J.|||0000-0001-9405-9748
  • Penzar, Dmitry D.
  • Vorontsov, Ilya E.
  • Favorov, A.V.
  • Forman, Julia R.
  • Hasenahuer, Marcia
  • Fornasari, Maria S.
  • Parisi, Gustavo|||0000-0001-7444-1624
  • Avsec, Ziga
  • Çelik, Muhammed H.
  • Nguyen, Thi Yen Duong
  • Gagneur, Julien|||0000-0002-8924-8365
  • Shi, Fang-Yuan
  • Edwards, Matthew D.|||0000-0002-3573-0025
  • Guo, Yuchun
  • Tian, Kevin
  • Zeng, Haoyang
  • Gifford, David K.
  • Göke, Jonathan
  • Zaucha, Jan|||0000-0003-3289-4590
  • Gough, Julian
  • Ritchie, Graham R.S.
  • Frankish, Adam|||0000-0002-4333-628X
  • Mudge, Jonathan M.
  • Harrow, Jennifer
  • Young, Erin L.
  • Yu, Yao|||0000-0002-2727-1746
  • Huff, Chad D.
  • Murakami, Katsuhiko
  • Nagai, Yoko
  • Imanishi, Tadashi
  • Mungall, Christopher J.
  • Jacobsen, Julius O.B.
  • Kim, Dongsup
  • Jeong, Chan-Seok
  • Jones, David T.
  • Li, Mulin Jun
  • Guthrie, Violeta Beleva
  • Bhattacharya, Rohit
  • Chen, Yun-Ching
  • Douville, Christopher
  • Fan, Jean
  • Kim, Dewey
  • Masica, David
  • Niknafs, Noushin
  • Sengupta, Sohini
  • Tokheim, Collin
  • Turner, Tychele N.
  • Yeo, Hui Ting Grace|||0000-0002-8920-8208
  • Karchin, Rachel
  • Shin, Sunyoung
  • Welch, Rene
  • Keles, Sunduz
  • Li, Yue
  • Kellis, Manolis
  • Corbi-Verge, Carles
  • Strokach, Alexey V.
  • Kim, Philip M.
  • Klein, Teri E.|||0000-0001-5527-6475
  • Mohan, Rahul
  • Sinnott-Armstrong, Nicholas A.
  • Wainberg, Michael
  • Kundaje, Anshul|||0000-0003-3084-2287
  • Gonzaludo, Nina
  • Mak, A.C.Y.
  • Chhibber, Aparna
  • Lam, Hugo Y.K.
  • Dahary, Dvir|||0000-0002-0974-8037
  • Fishilevich, S.
  • Lancet, Doron
  • Lee, Insuk
  • Bachman, Benjamin
  • Katsonis, Panagiotis
  • Lua, Rhonald C.
  • Wilson, Stephen J.
  • Lichtarge, Olivier
  • Bhat, Rajendra R.
  • Sundaram, Laksshman
  • Viswanath, Vivek
  • Bellazzi, Riccardo
  • Nicora, Nicora
  • Rizzo, Ettore
  • Limongelli, Ivan
  • Mezlini, Aziz M.
  • Chang, Ray
  • Kim, Serra
  • Lai, Carmen
  • O'Connor, Robert
  • Topper, Scott
  • van den Akker, Jeroen
  • Zhou, Alicia Y.
  • Zimmer, Anjali D.
  • Mishne, Gilad
  • Bergquist, Timothy R.
  • Breese, Marcus R.
  • Guerrero, Rafael F.|||0000-0002-8451-3609
  • Jiang, Yuxiang
  • Kiga, Nikki
  • Li, Biao
  • Mort, Matthew
  • Pagel, Kymberleigh A.
  • Pejaver, Vikas
  • Stamboulian, Moses H.
  • Thusberg, Janita
  • Mooney, Sean D.
  • Teerakulkittipong, Nuttinee|||0000-0002-2172-9277
  • Cao, Chen
  • Kundu, Kunal
  • Yin, Yizhou
  • Yu, Chen-Hsin
  • Kleyman, Michael
  • Lin, Chiao-Feng
  • Stackpole, Mary
  • Mount, Stephen M.
  • Eraslan, Gökcen
  • Mueller, Nikola S.
  • Naito, Tatsuhiko
  • Rao, Aliz R.
  • Azaria, Johnathan R.
  • Brodie, Aharon
  • Ofran, Yanay
  • Garg, Aditi
  • Pal, Debnath
  • Hawkins-Hooker, Alex
  • Kenlay, Henry
  • Reid, John
  • Mucaki, Eliseos J.
  • Rogan, Peter K.|||0000-0003-2070-5254
  • Schwarz, Jana M.
  • Searls, David B.
  • Lee, Gyu R.
  • Seok, Chaok
  • Krämer, Andreas
  • Shah, Sohela
  • Huang, ChengLai V.
  • Kirsch, Jack F.
  • Shatsky, Maxim
  • Cao, Yue
  • Chen, Haoran
  • Karimi, Mostafa
  • Moronfoye, Oluwaseyi
  • Sun, Yuanfei
  • Shen, Yang
  • Shigeta, Ron
  • Ford, Colby T.
  • Nodzak, Conor
  • Uppal, Aneeta
  • Shi, Xinghua
  • Joseph, Thomas
  • Kotte, Sujatha
  • Rana, Sadhna
  • Rao, Aditya
  • Saipradeep, Vangala G.
  • Sivadasan, Naveen
  • Sunderam, Uma
  • Stanke, Mario
  • Su, Andrew
  • Adzhubey, Ivan
  • Jordan, Daniel M.
  • Sunyaev, Shamil|||0000-0001-5715-5677
  • Rousseau, Frederic
  • Schymkowitz, Joost
  • Van Durme, Joost
  • Tavtigian, Sean V.
  • Carraro, Marco
  • Giollo, Manuel
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Adato, Orit|||0000-0002-2135-8947
  • Carmel, Liran|||0000-0003-0225-8550
  • Cohen, Noa E.|||0000-0002-4638-5407
  • Fenesh, Tzila
  • Holtzer, Tamar
  • Juven-Gershon, Tamar|||0000-0003-2607-5476
  • Unger, Ron
  • Niroula, Abhishek
  • Olatubosun, Ayodeji
  • Väliaho, Jouni
  • Yang, Yang
  • Vihinen, Mauno
  • Wahl, Mary E.
  • Chang, Billy
  • Chong, Ka C.
  • Hu, Inchi
  • Sun, Rui
  • Wu, William Ka Ke|||0000-0002-5662-5240
  • Xia, Xiaoxuan
  • Zee, Benny C.
  • Wang, Maggie Haitian|||0000-0003-1223-4595
  • Wang, Meng
  • Wu, Chunlei
  • Lu, Yutong
  • Chen, Ken
  • Yang, Yuedong
  • Yates, Christopher M.
  • Kreimer, Anat
  • Yan, Zhongxia
  • Yosef, Nir|||0000-0001-9004-1225
  • Zhao, Huying
  • Wei, Zhipeng
  • Yao, Zhaomin
  • Fengfeng, Zhou
  • Folkman, Lukas|||0000-0002-5811-8875
  • Zhou, Yaoqi
  • Daneshjou, Roxana|||0000-0001-7988-9356
  • Altman, Russ B.
  • Inoue, Fumitaka
  • Ahituv, Nadav
  • Arkin, Adam P.
  • Lovisa, Federica
  • Bonvini, Paolo
  • Bowdin, Sarah
  • Gianni, Stefano
  • Mantuano, Elide
  • Minicozzi, Velia
  • Novak, Leonore
  • Pasquo, Alessandra
  • Pastore, Annalisa|||0000-0002-3047-654X
  • Petrosino, Maria
  • Puglisi, Rita
  • Toto, Angelo
  • Veneziano, Liana
  • Chiaraluce, Roberta
  • Ball, Mad P.
  • Bobe, Jason R.
  • Church, George M.
  • Consalvi, Valerio
  • Cooper, David N.|||0000-0002-8943-8484
  • Buckley, Bethany A.
  • Sheridan, Molly B.
  • Cutting, Garry R.
  • Scaini, Maria Chiara|||0000-0002-9583-3034
  • Cygan, Kamil J.
  • Fredericks, Alger M.
  • Glidden, David T.
  • Neil, Christopher
  • Rhine, Christy L.|||0000-0002-5758-5543
  • Fairbrother, William G.
  • Alontaga, Aileen Y.
  • Fenton, Aron W.
  • Matreyek, Kenneth|||0000-0001-9149-551X
  • Starita, Lea M.
  • Fowler, Douglas M.
  • Löscher, Britt-Sabina
  • Franke, Andre|||0000-0003-1530-5811
  • Adamson, Scott I.
  • Graveley, Brenton R.
  • Gray, Joe W.
  • Malloy, Mary J.
  • Kane, John P.
  • Kousi, Maria
  • Katsanis, Nicholas
  • Schubach, Max
  • Kircher, Martin
  • Mak, Angel C.Y.
  • Tang, Paul L.F.
  • Kwok, Pui-Yan
  • Lathrop, Richard H.
  • Clark, Wyatt T.
  • Yu, Guoying K.
  • LeBowitz, Jonathan H.
  • Benedicenti, Francesco|||0000-0002-9458-0688
  • Bettella, Elisa
  • Bigoni, Stefania
  • Cesca, Federica
  • Mammi, Isabella
  • Marino-Buslje, Cristina|||0000-0002-6564-1920
  • Milani, Donatella
  • Peron, Angela|||0000-0002-1769-6548
  • Polli, Roberta
  • Sartori, Stefano
  • Stanzial, Franco
  • Toldo, Irene
  • Turolla, Licia
  • Aspromonte, Maria Cristina|||0000-0002-4937-6952
  • Bellini, Mariagrazia
  • Leonardi, Emanuela|||0000-0001-8486-8461
  • Liu, Xiaoming|||0000-0001-8285-5528
  • Marshall, Christian
  • McCombie, W. Richard
  • Elefanti, Lisa
  • Menin, Chiara
  • Meyn, M. Stephen
  • Murgia, Alessandra
  • Nadeau, Kari C.Y.
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Pirooznia, Mehdi|||0000-0002-4210-6458
  • Potash, James B.
  • Dimster-Denk, Dago F.
  • Rine, Jasper D.
  • Sanford, Jeremy R.
  • Snyder, Michael|||0000-0003-0784-7987
  • Cote, Atina G.
  • Sun, Song
  • Verby, Marta W.
  • Weile, Jochen
  • Roth, Frederick P.
  • Tewhey, Ryan
  • Sabeti, Pardis C.
  • Campagna, Joan
  • Refaat, Marwan M.
  • Wojciak, Julianne
  • Grubb, Soren
  • Schmitt, Nicole
  • Shendure, Jay
  • Spurdle, Amanda B.
  • Stavropoulos, Dimitri J.
  • Walton, Nephi A.
  • Zandi, Peter P.
  • Ziv, Elad
  • Burke, Wylie
  • Chen, Flavia
  • Carr, Lawrence R.
  • Martinez, Selena
  • Paik, Jodi
  • Harris-Wai, Julie
  • Yarborough, Mark|||0000-0001-8188-4968
  • Fullerton, Stephanie M.
  • Koenig, Barbara A.
  • McInnes, Gregory
  • Shigaki, Dustin
  • Chandonia, John-Marc
  • Furutsuki, Mabel
  • Kasak, Laura|||0000-0003-4182-2396
  • Yu, Changhua
  • Chen, Rui
  • Friedberg, Iddo
  • Getz, Gad A.
  • Cong, Qian
  • Kinch, Lisa N.
  • Zhang, Jing
  • Grishin, Nick V.
  • Voskanian, Alin
  • Kann, Maricel G.
  • Tran, Elizabeth
  • Ioannidis, Nilah M.
  • Hunter, Jesse M.
  • Udani, Rupa
  • Cai, Binghuang
  • Morgan, Alexander A.
  • Sokolov, Artem
  • Stuart, Joshua M.|||0000-0002-2171-565X
  • Minervini, Giovanni|||0000-0001-7013-5785
  • Monzon, Alexander M.
  • Batzoglou, Serafim
  • Butte, Atul J.
  • Greenblatt, Marc S.
  • Hart, Reece K.
  • Hernandez, Ryan
  • Hubbard, Tim J.P.
  • Kahn, Scott
  • O'Donnell-Luria, Anne|||0000-0001-6418-9592
  • Ng, Pauline C.
  • Shon, John
  • Veltman, Joris
  • Zook, Justin M.|||0000-0003-2309-8402
Background: The Critical Assessment of Genome Interpretation (CAGI) aims to advance the state-of-the-art for computational prediction of genetic variant impact, particularly where relevant to disease. The five complete editions of the CAGI community experiment comprised 50 challenges, in which participants made blind predictions of phenotypes from genetic data, and these were evaluated by independent assessors. Results: Performance was particularly strong for clinical pathogenic variants, including some difficult-to-diagnose cases, and extends to interpretation of cancer-related variants. Missense variant interpretation methods were able to estimate biochemical effects with increasing accuracy. Assessment of methods for regulatory variants and complex trait disease risk was less definitive and indicates performance potentially suitable for auxiliary use in the clinic. Conclusions: Results show that while current methods are imperfect, they have major utility for research and clinical applications. Emerging methods and increasingly large, robust datasets for training and assessment promise further progress ahead.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Ozkan, Selen
Endofenotip; Prediccions de patogenicitat; Predictor específic de proteïna, Endofenotipo; Predicciones de patogenicidad; Predictor específico de proteína, Endophenotype; Pathogenicity predictions; Protein-specific predictor, The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements., This research was funded by the EU European Regional Development Fund (ERDF) through the Program Interreg V-A Spain-France-Andorra (POCTEFA), grant number EFA086/15-PIREPRED, by the Spanish Ministerio de Ciencia e Innovación, grant number PID2019-111217RB-I00, and by the Spanish Ministerio de Economía y Competitividad, grant number SAF2016-80255-R.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

New genes involved in Angelman syndrome-like: Expanding the genetic spectrum

  • Aguilera, Cinthia
  • Gabau, Elisabeth
  • Ramirez-Mallafre, Ariadna
  • Brun-Gasca, Carme
  • Dominguez-Carral, Jana
  • Delgadillo, Veronica
  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
Síndrome de Angelman; Fenotipo, Síndrome d'Angelman; Fenotip, Angelman syndrome; Phenotype, Angelman syndrome (AS) is a neurogenetic disorder characterized by severe developmental delay with absence of speech, happy disposition, frequent laughter, hyperactivity, stereotypies, ataxia and seizures with specific EEG abnormalities. There is a 10–15% of patients with an AS phenotype whose genetic cause remains unknown (Angelman-like syndrome, AS-like). Whole-exome sequencing (WES) was performed on a cohort of 14 patients with clinical features of AS and no molecular diagnosis. As a result, we identified 10 de novo and 1 X-linked pathogenic/likely pathogenic variants in 10 neurodevelopmental genes (SYNGAP1, VAMP2, TBL1XR1, ASXL3, SATB2, SMARCE1, SPTAN1, KCNQ3, SLC6A1 and LAS1L) and one deleterious de novo variant in a candidate gene (HSF2). Our results highlight the wide genetic heterogeneity in AS-like patients and expands the differential diagnosis., This work is supported by Instituto de Salud Carlos III (MG, PI16/01411), Asociación Española de Síndrome de Angelman (EG), Institut d’investigació i innovació Parc Taulí I3PT (CA, CIR2016/025, CIR2018/021) and Ministerio de Economía y Competitividad (XD, SAF2016-14 80255-R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Álvarez de la Crespo, Elena
Predictors de patogenicitat in silico; Variants missense; Seqüenciació de nova generació, Predictores de patogenicidad in silico; Variantes missense; Secuenciación de nueva generación, In silico pathogenicity predictors; Missense variants; Next-generation sequencing, Background Strict guidelines delimit the use of computational information in the clinical setting, due to the still moderate accuracy of in silico tools. These guidelines indicate that several tools should always be used and that full coincidence between them is required if we want to consider their results as supporting evidence in medical decision processes. Application of this simple rule certainly decreases the error rate of in silico pathogenicity assignments. However, when predictors disagree this rule results in the rejection of potentially valuable information for a number of variants. In this work, we focus on these variants of the protein sequence and develop specific predictors to help improve the success rate of their annotation. Results We have used a set of 59,442 protein sequence variants (15,723 pathological and 43,719 neutral) from 228 proteins to identify those cases for which pathogenicity predictors disagree. We have repeated this process for all the possible combinations of five known methods (SIFT, PolyPhen-2, PON-P2, CADD and MutationTaster2). For each resulting subset we have trained a specific pathogenicity predictor. We find that these specific predictors are able to discriminate between neutral and pathogenic variants, with a success rate different from random. They tend to outperform the constitutive methods but this trend decreases as the performance of the constitutive predictor improves (e.g. with PON-P2 and PolyPhen-2). We also find that specific methods outperform standard consensus methods (Condel and CAROL). Conclusion Focusing development efforts on the case of variants for which known methods disagree we may obtain pathogenicity predictors with improved performances. Although we have not yet reached the success rate that allows the use of this computational evidence in a clinical setting, the simplicity of the approach indicates that more advanced methods may reach this goal in a close future., This work has been supported by the spanish Ministerio de Economía y Competitividad (BIO2012–40133; SAF2016–80255-R). It has also been supported, and the publication costs have been defrayed, by the European Regional Development Fund (ERDF), through the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014–2020), research grant PIREPRED (EFA086/15).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Choosing Variant Interpretation Tools for Clinical Applications: Context Matters

  • Aguirre, Josu
  • Padilla Sirera, Natàlia
  • Ozkan, Selen
  • Riera, Casandra
  • Feliubadaló, Lidia
  • De la Cruz Montserrat, Fco. Xavier
Clinical variant interpretation; Healthcare costs; Pathogenicity prediction, Interpretación de variantes clínicas; Costes sanitarios; Predicción de patogenicidad, Interpretació de variants clíniques; Despeses sanitàries; Predicció de patogenicitat, Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers., This work was supported by research grants SAF2016-80255-R from the Spanish Ministerio de Economía y Competitividad (MINECO), PID2019-111217RB-I00 and TED2021-130342B-I00 from the Spanish Ministerio de Ciencia e Innovación, and by the European Regional Development Fund (ERDF) through the Interreg program POCTEFA (Pirepred, EFA086/15).